(AGENPARL) - Roma, 3 Maggio 2024 - (AGENPARL) – ven 03 maggio 2024 8.00 AM CEST / 3-May-2024 / Hansa Biopharma AB (STO:HNSA)
Lund, Sweden May 3, 2024. Hansa Biopharma AB (publ), (“Hansa” or the “Company”)
(Nasdaq Stockholm: HNSA) today announced that the company’s registered share
capital and number of shares and votes have increased through the issue of
10,474,740 new ordinary shares on 12 April 2024, whereby the number of votes
increased with 10,474,740 and the share capital increased with SEK 10,474,740.
As of today, the total number of registered shares of the company amounts to
65,508,981, whereof 63,146,536 are ordinary shares and 2,362,445 are class C
shares. As of today, the number of votes in the company amounts to 63,382,780.5,
and the registered share capital amounts to SEK 65,508,981.
The information in the press release is information that Hansa Biopharma AB
(publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
persons above, on May 3, 2024 at 08:00 (CEST).
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life altering
treatments for patients with rare immunological conditions. Hansa has developed
a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which
has been shown to enable kidney transplantation in highly sensitized patients.
Hansa has a rich and expanding research and development program, based on the
Company’s proprietary IgG-cleaving enzyme technology platform, to address
serious unmet medical needs in transplantation, autoimmune diseases, gene
therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at www.hansabiopharma.com.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/31ocDrcFRCjUveB7rKX93qE6c3azNMgkCcEDiNwCKPtUmfkHUzXt27f8d7eA1swpeAy8RaEoT9B23hb6KT1q1kHe5WCqJQt7ZNVbAwYW12cyH4.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/31ocDrcFRCjUveB7rKX93qE6c3azNMgkCcEDiNwCKPtUmfkHUzXt27f8d7eA1swpeAy8RaEoT9B23hb6KT1q1kHe5WCqJQt7ZNVbAwYW12cyH4.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Trending
- POLIZIA DI STATO-Cordoglio Capo della Polizia Prefetto Pisani
- [Comune Palermo] Piscina comunale. Consegnati lavori vasche
- DE GENNARO. ROTONDI (FDI): ‘HA RAGIONE CASINI,OGGI LA MAFIA BRINDA
- De Gennaro: Ronzulli (FI), pensiero a famiglia, basta processi mediatici
- Comunicato Stampa 2055/2026 Domegge, altri 190.000 euro dal Fondo Comuni confinanti per gli impianti di atletica. Bond: “Finanziamento sale a 1,69 mln. Previsti tribune coperte, spogliatoi, locali di servizio
- Manovra, Bonelli (AVS): «Pagano pensionati e famiglie, ci guadagnano le lobby e l’industria delle armi»
- PINETA GRANDE, ZINZI (LEGA): “BENE ACCORDO CHE SCONGIURA CHIUSURA PRONTO SOCCORSO, MA FICO NON SCAMBI UNA TOPPA PER LA SOLUZIONE
- COMUNICATO STAMPA – Pesca: Battistoni (FI), patrimonio economico del Paese
- Agenzia nr. 2222 – Medicina generale, Ferri (FdI): “Non è in gioco solo il Cpt di Trani ma l’intero modello di assistenza territoriale
- Permessi di sosta personalizzati, l’assessore Bongiorni: “In primo piano la tutela dei diritti e il contrasto agli abusi